A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Completed · Phase 3 · NCT04009499
Conditions: Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $161,498
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 1,131
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Bimekizumab (drug)
- Dates
- Started 2019-08-13; completion 2026-05-26
- Results posted
- Not yet
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
From ClinicalTrials.gov, last updated 2026-09-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $161,498 in research payments for this study in 2025 (20 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tania L. Rivera, M.D. Rheumatology · Escondido, CA
- Vipul M. Joshi, MD Specialist · Brandon, FL
- James E. Loveless, MD Rheumatology · Boise, ID
- Mary P. Howell, MD Internal Medicine · Hagerstown, MD
- Joshua P. June, DO Rheumatology · Lansing, MI
- Jane H. Box, MD Rheumatology · Charlotte, NC
- Leroy A. Pacheco, MD Rheumatology · Albuquerque, NM
- Ahuva Cices, MD Dermatology · New York, NY
- David H. Goddard, MD Rheumatology · Brooklyn, NY
- Sanford M. Wolfe, DO Rheumatology · Dayton, OH
- Alan Kivitz, MD Rheumatology · Duncansville, PA
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Jacob Aelion, M.D. Specialist · Jackson, TN
- Ramesh C. Gupta I, M.D. Specialist · Memphis, TN
- Anurekha B. Chadha, MD Rheumatology · Austin, TX
- Joseph F. Merola, M.D., M.M.SC. Dermatology · Dallas, TX
- Atul K. Singhal, M.D. FACR Rheumatology · Mesquite, TX
- Wassim S. Saikali, MD Rheumatology · Beckley, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn Institute/genetics $33,817
- Djl Clinical Research PLLC $25,507
- Albuquerque Center for Rheumatology $19,058
- Weitzner, Yonker, Kaine MD. $14,097
- Southwest Rheumatology Research LLC $14,038
- Klein & Associates MD PA $12,139
- Premier Clinical Research $11,208
- Summit Rheumatology - Rheumatology and Pulmonary Clinic $10,935
- $7,335
- New York University $3,820
- Rheumatology Center of San Diego PC $3,052
- West Tennessee Research Institute $1,800
- Shelby Research LLC $1,572
- St Luke's Regional Medical Center, ID $1,518
- Clinical PArtners LLC $830
- June Do PC $638
- Austin Regional Clinic $131
- Brigham and Women's Hospital, MA $2
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.